Trial · NCT07533721
Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort
NCT07533721, Completed, Shengjing Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort. Trials, record NCT07533721. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07533721
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort
- NCT number
- NCT07533721
- Status
- Completed
- Enrollment
- 541 participants, actual
- Lead sponsor
- Shengjing Hospital
- Conditions
- Patent Ductus Arteriosus, Infant, Premature
- Interventions
- Ibuprofen
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with PDA Closure | At day 7 after intervention start (or equivalent time point for expectant management group) | Proportion of preterm infants with echocardiographically confirmed closure of hemodynamically significant patent ductus arteriosus (hsPDA). |
| Secondary | Number of Participants with Bronchopulmonary Dysplasia (BPD) | At 36 weeks postmenstrual age (measured between 35+0 and 36+6 weeks) | Description: BPD defined as need for supplemental oxygen or respiratory support at 36 weeks postmenstrual age. |
| Secondary | Number of Participants who Died (All-cause Mortality) | From birth to hospital discharge, up to 28 days | Death from any cause during the neonatal period. |
| Secondary | Number of Participants with Pulmonary Hypertension | During initial hospitalization, up to 12 weeks | Echocardiographic evidence of elevated pulmonary artery pressure. |
| Secondary | Number of Participants with Renal Insufficiency | Within first 7 days after intervention start | Serum creatinine \>1.5 mg/dL or oliguria (\<1 mL/kg/h for 24 hours). |
| Secondary | Number of Participants with Neonatal Pneumonia | During initial hospitalization, up to 12 weeks | Clinical and radiographic diagnosis of pneumonia |
| Secondary | Number of Participants with Retinopathy of Prematurity (ROP) | Prior to discharge or at 40 weeks postmenstrual age, up to 16 weeks | Any stage of ROP as diagnosed by ophthalmologic examination. |
| Secondary | Number of Participants with Intraventricular Hemorrhage (IVH) | Within first 14 days of life | Any grade of IVH diagnosed by cranial ultrasound. |
| Secondary | Number of Participants with Pulmonary Hemorrhage | During initial hospitalization, up to 12 weeks | Sudden deterioration with bloody tracheal aspirate confirmed by chest radiograph. |
| Secondary | Number of Participants with Gastrointestinal Bleeding | Within first 7 days after intervention start | Melena, hematemesis, or bloody gastric aspirate requiring intervention. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07533721
GET https://conductscience.org/api/trials/v1/NCT07533721/registered